TRV 027

Drug Profile

TRV 027

Alternative Names: Beta-arrestin biased ligand - Trevena; MPS-418; TRV-120027; TRV027; β-arrestin biased ligand - Trevena

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trevena
  • Class Heart failure therapies; Oligopeptides; Vasodilators
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Beta-arrestin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute heart failure

Most Recent Events

  • 15 Apr 2016 Trevena completes enrolment in a phase II trial for Acute heart failure (NCT01966601)
  • 04 Dec 2015 Trevena has patent protection for TRV 027 in Europe
  • 30 Jun 2015 TRV 027 is still in phase II trials for Acute heart failure (Combination therapy, First-line therapy) in USA, Argentina, Bulgaria, Canada, Czech Republic, Hungary, Germany, Israel, Poland, Romania, Russia and Slovakia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top